In partnership with Rennes University Teaching Hospital, the Eugène Marquis Centre coordinates the INCa-designated early-phase clinical trial centres (CLIP2) [Centre Labellisé par l’INCa (Institut National du Cancer) de Phases Précoces] programme for Brittany. The CLIP2 department comprises an oncologist, a haematologist–oncologist and a pneumologist–oncologist and covers all malignant diseases present in adults.
The department has worked to bring the Centre and Rennes University Teaching Hospital closer together on both a medical and an organisational level; it works with regional and interregional organisations to improve access to innovative treatments for all patients in Brittany at Rennes University Teaching Hospital.
On its initiative, a multidisciplinary team meeting (RCP) [Réunion de Concertation Pluridisciplinaire] on molecular biology was introduced in collaboration with the molecular biology team in Rennes to further develop the characterisation of cancers and increase access to targeted therapy trials for patients with certain genetic anomalies (personalised medicine).
The CLIP2 department is greatly involved in developing new immunotherapy treatments to revolutionise the treatment of cancer, while at the same time ensuring patient safety (TOXI2 staff) (Toxicity of Innovative Immunotherapies [Toxicité des Immunothérapies Innovantes].
In collaboration with the Brittany Regional Cancerology Institute [Pôle Régional de Cancérologie Bretagne] and the Nantes–Angers Comprehensive Cancer Centre (CCC) [Centre de Lutte Contre le Cancer], CLIP2 serves as the operational framework for staff who are members of the Grand-Ouest Early Access to Research network (ARPEGO) [Accès à la Recherche Précoce dans le Grand-Ouest], which helps patients in Brittany for whom treatment has been ineffective to gain early access to new therapies.